Applications are being accepted until tomorrow February
28, 2017
Learn how to apply HERE
MedTech Innovator – working in collaboration with AdvaMed –
will award over $500K in cash prizes, scholarships, and in-kind awards in 2017
to early- to mid-stage companies developing medical devices, diagnostics, and
digital health technologies. The program includes access to regional
pitch events, a chance to participate in an accelerator program, and to compete
for cash awards during the Final Pitch Competition at AdvaMed 2017 in San Jose, CA.
For more info, please
visit MedTech
Innovator
90 min Webinars starting at 1:00PM ET
March 6-15, 2017
Learn more and REGISTER HERE
The US Patent and Trademark Office (USPTO) will present seven
FREE webinars surrounding Intellectual Property (IP) for individuals
and small businesses that have been awarded grants through the NIH SBIR/STTR program.
It is necessary to
protect your ideas, products, and product names in today’s economy!
View the list of webinar topics:
March
6: Overview: US Intellectual
Property Rights and the SBIR-STTR Stakeholders
Presenter: Henry Wixon
March
7: Trademarks in the U.S.
Presenter: Scott Baldwin
March
8: The International Trademark
Portfolio
Presenter: Susan Anthony
March
9: Copyright (Domestic and
International)
Presenter: Susan Anthony
March
13: Basic US Patent Practice for
the SBIR-STTR Stakeholders
Presenter: Michael Razavi
March
14: Patent Cooperation Treaty (PCT)
and Hague Strategies for Filing Abroad
Presenter: Layla Lauchman
March 15: Intermediate/Advanced US Patent Practice for
the SBIR-STTR Stakeholders
Presenter: Oleg Asanbaye
For more info, please visit USPTO
The Commercialization
Readiness Pilot (CRP) Program Solicitation(s) pilot program is set to expire
Sept 30, 2017. The last receipt date for Commercialization
Readiness Pilot (CRP) program (PAR-16-026, also see NHLBI Notice of
Correction NOT-HL-15-283) will be Apr 5, 2017.
Seek NHLBI guidance while writing your Bridge
and Small Market Applications
Apply for up to $3M to
support continued development of your Phase II SBIR or STTR-funded heart, lung,
blood, or sleep technology requiring approval or clearance by a Federal
regulatory agency. The National Heart, Lung, and Blood Institute (NHLBI) SBIR Phase IIB Bridge
and Small Market Awards programs aim to de-risk your technology and encourage partnerships
between small businesses and investors and strategic partners.
Letters of Intent due May 19, 2017.
Applications due June 19, 2017.
For more information, please read the full Notice:
The International Council for Harmonisation (ICH) recently announced that it is requesting
public comment on a “Reflection Paper” outlining a proposed
approach to revising and modernizing the ICH Guidelines for clinical trial
design, planning, management and conduct. The planned modernization,
which would affect the current E8 General Considerations for Clinical Trials
and the E6 Guideline for Good Clinical Practice, addresses the
increasing diversity of study types and data sources that are used to support
regulatory and health policy decisions.
Submit comments to gcprenovation@ich.org by March 11, 2017.
The Center for Drug Evaluation and Research’s Small Business and
Industry Assistance office has just launched a new web-based learning tutorial:
Best
Practices for Communication Between FDA and IND Sponsors During Drug
Development. The one-hour course describes best practices and
procedures for timely, transparent, and effective communications between
investigational new drug application (IND) sponsors and FDA at critical
junctures in drug development.
FDA hosted a webinar to share information and answer questions
about the final guidance document, “Medical
Device Accessories: Describing Accessories and Classification Pathway for New
Accessory Types.” The purpose of this document is to provide
recommendations to industry about the regulation of accessories to medical
devices. The guidance provides clarification on the definition of a medical
device accessory. It recommends classifying accessories according to their
level of risk when used as intended with a parent device to ensure their safety
and effectiveness while reducing burden to manufacturers. It also encourages
manufacturers to use the de novo process to request risk-based classification
for new accessories when appropriate. A transcript, recording, and the
slide presentation are available at: http://www.fda.gov/CDRHWebinar.
03/09 – BD Boston Biotech
Conference 2017 - Boston, MA
03/12 – 03/15 – AUTM 2017 Annual Meeting - Hollywood, FL
03/17 – 03/19 – American College of Cardiology (ACC. 17) –
Washington, DC
03/23 –
3/25 - Venture Well – Washington, DC
03/30 –
3/31 - AdvaMed Innovation Summit – Washington,
DC
|
